Skip to main content
Caplight Logo









iXgene Inc.

iXgene Inc.

Private
JapanHealthcare & Life Scienceshttps://www.ixgene.inc/

Last Round

Series A

Jan 5, 2023

Total Funding Raised

$4.5M

Company Overview

iXgene Inc. is a biotechnology company that develops innovative cell therapies for intractable diseases, such as malignant brain tumors, by utilizing genome-edited iPS cell-derived neural stem cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

regenerative medicinecell therapyinduced pluripotent stem cellsiPS cellsgenome editingmalignant brain tumorglioblastoma treatmentneural stem cellssuicide gene therapybiotech startupprecision medicinedrug delivery platformblood-brain barrierbiotech R&Dcell engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iXgene Inc. Comparables

Compare iXgene Inc. with similar companies based on industry and business-model similarity.

iXgene Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CELLeBRAIN
80%
Shinobi Therapeutics, Inc.
79%
Trogenix
71%

iXgene Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 5, 2023
SeedOct 1, 2020

Key People

Founding team and executive leadership

Atsushi Mizuno

Representative Director, COO

Executive Team

iXgene Inc. Investors

Notable investors and investment history

iXgene Inc. investors
InvestorRounds
Keio Innovation InitiativeSeries A
MSF Capital PartnersSeries A
UTokyo Innovation Platform Co., Ltd.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors increased 43% MoM.

  • Jan 5, 2023

    $4.5M round led by Keio Innovation Initiative.

iXgene Inc. Filings

Explore SEC and related filing metadata, where available.

iXgene Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iXgene Inc.'s valuation, stock price, and market status.

Is iXgene Inc. a public or private company?

iXgene Inc. is a private company.

What is the current stock price of iXgene Inc.?

iXgene Inc. is a private company with no public stock price. Caplight tracks iXgene Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is iXgene Inc. worth (valuation)?

Valuation information for iXgene Inc. is not publicly available.

Can I buy iXgene Inc. stock?

iXgene Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iXgene Inc.'s last funding round?

iXgene Inc.'s most recent funding round was Series A on January 5, 2023.

Who are the main investors in iXgene Inc.?

Key investors in iXgene Inc. include Keio Innovation Initiative.

Will iXgene Inc. IPO soon?

No public IPO plans have been announced for iXgene Inc..

How can I track iXgene Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iXgene Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersJapan
Employee Range1
Year Founded2020
Last FundingJan 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?